501 related articles for article (PubMed ID: 31211526)
41. Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospective observational study using regression methods.
Kessler S; Desai M; McConnell W; Jai EM; Mebine P; Nguyen J; Kiroyan C; Ho D; Von Schweber E; Von Schweber L
J Manag Care Spec Pharm; 2021 Sep; 27(9):1186-1196. PubMed ID: 34032130
[No Abstract] [Full Text] [Related]
42. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
[TBL] [Abstract][Full Text] [Related]
43. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
Rothbard AB; Lee S; Blank MB
J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
[TBL] [Abstract][Full Text] [Related]
44. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
45. Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.
Nazareth T; Li N; Marynchenko M; Zhou Z; Chopra P; Signorovitch J; Wu E; Ahmed S; Marvel J; Sasane R
Curr Med Res Opin; 2016; 32(3):405-16. PubMed ID: 26565934
[TBL] [Abstract][Full Text] [Related]
46. Pennsylvania's Medical Home Initiative: Reductions in Healthcare Utilization and Cost Among Medicaid Patients with Medicaland Psychiatric Comorbidities.
Rhodes KV; Basseyn S; Gallop R; Noll E; Rothbard A; Crits-Christoph P
J Gen Intern Med; 2016 Nov; 31(11):1373-1381. PubMed ID: 27353455
[TBL] [Abstract][Full Text] [Related]
47. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.
Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ
J Gastroenterol Hepatol; 2017 Jan; 32(1):229-236. PubMed ID: 27197716
[TBL] [Abstract][Full Text] [Related]
48. Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
Schiff L
Clin Ther; 2015 May; 37(5):1092-112. PubMed ID: 25850880
[TBL] [Abstract][Full Text] [Related]
49. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.
McDonald SA; Azzeri A; Shabaruddin FH; Dahlui M; Tan SS; Kamarulzaman A; Mohamed R
Appl Health Econ Health Policy; 2018 Dec; 16(6):847-857. PubMed ID: 30145775
[TBL] [Abstract][Full Text] [Related]
50. Treating Medicaid patients with hepatitis C: clinical and economic impact.
Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
[TBL] [Abstract][Full Text] [Related]
51. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
[TBL] [Abstract][Full Text] [Related]
52. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
54. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
55. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation.
Cenderello G; Taramasso L; Marra D; Orcamo P; Pasa A; Di Biagio A
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):189-193. PubMed ID: 30321071
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness of the Hepatitis C Self-Management Program.
Groessl EJ; Sklar M; Laurent DD; Lorig K; Ganiats TG; Ho SB
Health Educ Behav; 2017 Feb; 44(1):113-122. PubMed ID: 27206463
[TBL] [Abstract][Full Text] [Related]
57. Current and future health and economic impact of hepatitis C in Belgium.
Vandijck D; Moreno C; Stärkel P; Van Damme P; Van Vlierberghe H; Hindman SJ; Razavi H; Laleman W
Acta Gastroenterol Belg; 2014 Jun; 77(2):285-90. PubMed ID: 25090835
[TBL] [Abstract][Full Text] [Related]
58. The economic burden of schizophrenia in the United States in 2002.
Wu EQ; Birnbaum HG; Shi L; Ball DE; Kessler RC; Moulis M; Aggarwal J
J Clin Psychiatry; 2005 Sep; 66(9):1122-9. PubMed ID: 16187769
[TBL] [Abstract][Full Text] [Related]
59. Short-term budget affordability of hepatitis C treatments for state Medicaid programs.
Chou JW; Silverstein AR; Goldman DP
BMC Health Serv Res; 2019 Feb; 19(1):140. PubMed ID: 30819153
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
